| Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. | |
| | |
MedLine Citation:
|
PMID: 17679700 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A recent, widely publicized meta-analysis of 42 clinical trials concluded that rosiglitazone was associated with an approximately 43% increased risk for myocardial infarction and an approximately 64% increased risk for cardiovascular death. The sensitivity of these conclusions to several methodological choices was not assessed. The meta-analysis was not based on a comprehensive search for all studies that might yield evidence about rosiglitazone's cardiovascular effects. Studies were combined on the basis of a lack of statistical heterogeneity, despite substantial variability in study design and outcome assessment. The meta-analytic approach that was used required the exclusion of studies with zero events in the treatment and control groups. Alternative meta-analytic approaches that use continuity corrections show lower odds ratios that are not statistically significant. We conclude that the risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone is uncertain: Neither increased nor decreased risk is established. |
| | |
Authors:
|
George A Diamond; Leon Bax; Sanjay Kaul |
Publication Detail:
|
Type: Journal Article Date: 2007-08-06 |
Journal Detail:
|
Title: Annals of internal medicine Volume: 147 ISSN: 1539-3704 ISO Abbreviation: Ann. Intern. Med. Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2007-10-16 Completed Date: 2007-11-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0372351 Medline TA: Ann Intern Med Country: United States |
Other Details:
|
Languages: eng Pagination: 578-81 Citation Subset: AIM; IM |
Affiliation:
|
Cedars-Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA. gadiamond@pol.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiovascular Diseases
/
chemically induced,
mortality* Diabetes Mellitus, Type 2 / drug therapy* Humans Hypoglycemic Agents / adverse effects* Meta-Analysis as Topic Myocardial Infarction / chemically induced* PPAR gamma / agonists Research Design / standards Risk Factors Thiazolidinediones / adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/PPAR gamma; 0/Thiazolidinediones; 122320-73-4/rosiglitazone |
| Comments/Corrections | |
Comment In:
|
Ann Intern Med. 2007 Oct 16;147(8):585-7
[PMID:
17938398
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: beta-Catenin regulates excitatory postsynaptic strength at hippocampal synapses.
Next Document: Geriatric conditions and disability: the Health and Retirement Study.